Meet Ajit Bisen, M.D.
Ajit K. Bisen, M.D., MBA
Department of General Oncology, Division of Cancer Medicine
About Dr. Ajit K. Bisen
I am an Associate Professor in the Departments of General Oncology and Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. My clinical practice is dedicated exclusively to the care of patients with breast cancer, with a focus on delivering high-quality, patient-centered care through multidisciplinary collaboration and clinical innovation.
My clinical and academic interests center on emerging therapeutic frontiers, including radioligand therapy, a novel theranostic approach that enables targeted detection and treatment of cancer, as well as neuroendocrine tumors of the breast—particularly poorly differentiated neuroendocrine carcinoma, a rare and recently characterized subtype for which optimal treatment paradigms continue to evolve.
I serve in key leadership roles as Faculty Wellness Officer for General Oncology and Associate Patient Safety and Quality Officer (PSQO) for Breast Medical Oncology, where I focus on fostering physician well-being and advancing safe, reliable, and high-quality care through system-level improvements.
My research efforts include early-phase clinical trials in radioligand therapy and focused work in neuroendocrine breast cancer, alongside active participation in institution-wide clinical trials aimed at expanding access to innovative therapies and improving patient outcomes.
Beyond MD Anderson, I serve as President-Elect of the Texas Society of Clinical Oncology (TxSCO) (Presidency term: October 2026 – October 2028), contributing to statewide education, collaboration, and advocacy, while also engaging in mentorship and community outreach.
Across all roles, my goal is to advance the standard of cancer care while building systems that support both patients and healthcare teams in delivering meaningful, safe, and effective outcomes.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor (Secondary Appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Affiliate Faculty, Clinical Cancer Genetics Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2018 | UT Dallas Jindal School of Management, Dallas, Texas, US, MBA, Healthcare Leadership and Management |
| 2009 | St. George’s University School of Medicine, St. George, GD, M.D |
| 2004 | University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US, B.S. Computer Science |
Postgraduate Training
| 2017-2020 | Clinical Fellowship, Hematology and Oncology, UT Southwestern Medical Center, Dallas, Texas |
| 2013-2014 | Clinical Fellowship, Hematology and Oncology, The Ohio State University, Columbus, Ohio |
| 2009-2012 | Clinical Residency, Internal Medicine, Penn State University Hershey Medical Center, Hershey, Pennsylvania |
Licenses & Certifications
| 2023 | Georgia Composite Medical Board |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Florida Board of Medicine |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2023 | Alabama Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2022 | DEA |
| 2020 | American Board of Hematology |
| 2020 | American Board of Medical Oncology |
| 2013 | Texas Medical Board |
| 2012 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2025
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2025
Assistant Professor, The University of Texas Southwestern Medical Center, Dallas, Texas, 2014 - 2017
Assistant Professor, Parkland Hospital, Dallas, Texas, 2014 - 2015
Clinical Assistant Professor of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, 2013 - 2013
Assistant Professor, Lebanon VA Medical Center, Lebanon, Pennsylvania, 2012 - 2013
Administrative Appointments/Responsibilities
Dept of General Oncology Faculty Lead at West Houston HAL, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Other Professional Positions
President Elect, Texas Society of Clinical Oncology, Texas, 2024 - Present
Affiliate Faculty Collaborator and Student Mentor, Pre-Health Honors Research Course, Baylor University, Office of Pre-Health Studies, Baylor University, Waco, Texas, 2024 - Present
MD Anderson Cancer Center Community Relations Ambassador, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Medical Advisory Board Member, Indian American Cancer Network (iacannetwork.org), 2023 - Present
Assistant Professor, Oncology Hospitalist, UT Southwestern Medical Center, Dallas, Texas, 2015 - 2017
Extramural Institutional Committee Activities
Associate Quality Officer, Breast Medical Oncology Quality Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Tumor Board Co-Moderator, Department of Breast Medical Oncology Weekly Case Conference, The University of Texas MD Anderson Cancer Center, 2024 - Present
Faculty Wellness Officer, Department of General Oncology, Wellness Working Group, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2024 - Present
Tumor Board Moderator, Breast Oncology Weekly Multidisciplinary Tumor Board, West Houston HAL, The University of Texas MD Anderson Cancer Center, 2024 - Present
Patient Safety Officer, MD Anderson West Houston HAL Quality and Safety Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, MD Anderson IRB Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Member, Internal Guideline Committee for Breast Lobular Carcinoma, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Multidisciplinary Breast Tumor Board planning committee, West Houston HAL, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Wellness Working Group, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2021 - Present
Editorial Activities
Faculty, Project ECHO teleconsulting and tele mentoring global outreach participating faculty, 2024 - Present
Reviewer, International second opinion consultations for breast cancer cases from the Middle East, 2023 - Present
Site Leader, TheMednet.org, UT MD Anderson Department of Breast Medical Oncology for tumor board question submission and review, 2021 - Present
Honors & Awards
| 2024 | Ranked Top 1% Nationally, Consumer Assessment of Healthcare Providers and Systems (CAHPS), The University of Texas MD Anderson Cancer Center |
| 2022 | Highest Award for Achievement, Dale Carnegie Effective Communications and Human Relations Program |
| 2018 | Outstanding Fellow Recognition Award, Texas Society of Clinical Oncology |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Right Care, Right Place: Improving Urgent Care for Breast Cancer Patients on Chemotherapy. Invited. Ambulatory Celebrate Improvement Fair 2026. Houston, Texas, US.
- 2024. Multidisciplinary approaches to SLN and ALND omission based on the SOUND, SENOMAC, and AMAROS trials. Invited. Breast Cancer Clinical and Translational Research (BCCTR) Conference. Houston, Texas, US.
- 2024. Multidisciplinary Approach to Early-Stage Breast Cancer Management. Conference. Research Educational Series. Houston, TX, US.
- 2024. First Diagnosis of Metastatic Breast Cancer. Invited. BMO Research Educational Series. Houston, Texas, US.
- 2024. The Prevalence of and Progress in Breast Cancer Management. Invited. IACAN (Indian American Cancer Network) Annual Breast Health Awareness Program. Houston, Texas, US.
- 2024. Multidisciplinary Approach to Early-Stage Breast Cancer Management. Conference. Breast Medical Oncology Educational Meeting, US.
- 2024. Treatment Crossroads: What is your approach to treating patients after CDK 4/6 progression?. Invited. OncLive State of the Science Summit: Breast Cancer. Houston, Texas, US.
- 2024. Hormone Receptor Positive Metastatic Breast Cancer. Invited. Grand Round Presentation. Houston, Texas, US.
- 2024. Career Day Speaker. Invited. Houston, Texas, US.
- 2018. New Kids on the Block, SERD, PROTAC, and CERANs. Updates in Advanced Breast Cancer Conference. Invited. Houston, Texas, US.
Regional Presentations
- 2025. Systematic Review: Mammogram Access Challenges for Uninsured and Underinsured Women in Texas. Poster. TxSCO (Texas Society of Clinical Oncology) Annual Conference. Houston, TX, US.
- 2024. Physician Burnout and Wellness in the Healthcare Environment. Invited. TxSCO (Texas Society of Clinical Oncology) Annual Conference. San Antonio, Texas, US.
- 2023. Recent Advances and Updates in Breast Cancer Research and Treatment. Invited. Texas Society of Clinical Oncology Annual Conference, Texas, US.
- 2018. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. Poster. TxSCO (Texas Society of Clinical Oncology) Annual Conference. Houston, Texas, US.
National Presentations
- 2026. Genomic Landscape and Survival Outcomes in Breast Neuroendocrine Carcinoma: A Descriptive Institutional Cohort Analysis. Poster. AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers. Vancouver, BC, CA.
- 2025. Impact of Targeted Interventions on Reducing Emergency Department Visits in Breast Cancer Patients Receiving Chemotherapy. Poster. ASCO Quality Care Symposium. Boston, MA, US.
- 2025. Hormone Receptor Positive, HER2 Negative Breast Cancer. Invited. Nevada Oncology Society Official Review of SABCS. Las Vegas, NV, US.
- 2011. Multiplex plasma biomarkers associated with bone metastasis from breast cancer. Conference. 34th San Antonio Breast Cancer Symposium. San Antonio, TX, US.
International Presentations
- 2017. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. Conference. IASLC - International Association for the Study of Lung Cancer. Santa Monica, US.
Formal Peers
- 2023. Updates in Management of Breast Cancer, Monthly Education Series, MD Anderson West Houston. Houston, Texas, US.
Selected Publications
Peer-Reviewed Articles
- Shaker, S, Patel, D, Bisen, AK, Ramirez, DL. Impact of targeted interventions on reducing emergency department visits in breast cancer patients receiving chemotherapy. JCO Oncology Practice 21:433, 2025. e-Pub 2025.
- Shaker, S, Patel, D, Bisen, AK, Sun, SX, Ramirez, DL. Right care, right place: Improving urgent care for breast cancer patients on chemotherapy. Journal of Clinical Oncology 43:e23229-e23229, 2025. e-Pub 2025.
- Yam, C, Patel, MM, Hill, H, Sun, R, Bassett Jr, R, Kong, EK, Damodaran, S, Koenig, KB, Abouharb, S, Saleem, S, Bisen, AK, Murthy, RK, Ramirez, DL, Rauch, GM, Adrada, BE, Candelaria, RP, Wang, X, Mittendorf, EA, Thompson, A, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Booser, DJ, Oke, OC, Brewster, A, Hortobagyi, GN, Ibrahim, NK, Litton, J, Valero, V, Arun, BK, Tripathy, D, Chang, J, Chen, K, Korkut, A, Moulder, S, Huo, L, Lim, B, Ueno, NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research Communications 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
- Chamani, IJ, Gannon, A, Connell, PT, Bisen, AK, Kovanci, E, Sangi-Haghpeykar, H, Woodard, TL, McKenzie, LJ. Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve. Journal of adolescent and young adult oncology 13(3):465-468, 2024. e-Pub 2024. PMID: 38112555.
- Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer 119(8):928-936, 2018. e-Pub 2018. PMID: 30318513.
- Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12(10):1489-1495, 2017. e-Pub 2017. PMID: 28802905.
Review Articles
- Bisen A, Claxton DF. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv Exp Med Biol 779:179-96, 2013. e-Pub 2013. PMID: 23288640.
Abstracts
- Bisen A. Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer. AACR, 2023. e-Pub 2023.
- Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Tripathy D. Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer, 2022. e-Pub 2022.
- Leitzel K, Ali S, Bisen A, Lomakin A, Simonyan V, Lipton A. Multiplex plasma biomarkers associated with bone metastasis from breast cancer. American Association for Cancer Research 71(24), 2011. e-Pub 2011.
Book Chapters
- Bisen AK, Claxton D. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. In: Advances in Experimental Medicine and Biology. Springer.
Web Publications
- Bisen AK. Deep vein thrombosis as a side effect of cancer: 9 things to know, 2023.
- Bisen AK. Is it safe for my partner going through cancer treatment to be around our family pet?, 2023.
- Bisen AK. Edema and cancer: 8 questions answered, 2023.
- Bisen AK. 8 do’s and don’ts for pet owners during cancer treatment, 2023.
- Bisen AK. Cancer glossary: 13 terms to know about your diagnosis, 2022.
Patient Reviews
CV information above last modified July 22, 2026